Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Stock Information for Fortress Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc.

Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Fortress Biotech to Participate in October 2024 Investor Conferences
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Journey Medical Corporation to Participate in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.